XTX Topco Ltd Has $1.63 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

XTX Topco Ltd raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 69.9% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 61,341 shares of the biopharmaceutical company’s stock after purchasing an additional 25,231 shares during the period. XTX Topco Ltd’s holdings in Pfizer were worth $1,627,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the fourth quarter valued at $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $28,000. Noble Wealth Management PBC acquired a new position in Pfizer in the fourth quarter worth approximately $31,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer during the fourth quarter valued at approximately $33,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.9 %

Shares of NYSE PFE opened at $22.10 on Tuesday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market cap of $125.34 billion, a P/E ratio of 15.67, a P/E/G ratio of 0.64 and a beta of 0.67. The firm has a 50 day moving average price of $25.16 and a 200 day moving average price of $26.33.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.10 EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 0.06% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on PFE. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group reduced their target price on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday, April 8th. Finally, Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $31.07.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.